Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/30173
Tipo de documento
ArtigoDireito Autoral
Acesso restrito
Data de embargo
2025-08-30
Coleções
- INI - Artigos de Periódicos [3399]
Metadata
Mostrar registro completo
EFFICACY AND SAFETY OF ETRAVIRINE AT WEEK 96 IN TREATMENT-EXPERIENCED HIV TYPE-1-INFECTED PATIENTS IN THE DUET-1 AND DUET-2 TRIALS
Double-Blind Method
Darunavir
Reverse Transcriptase Inhibitors
Ritonavir
Treatment Outcome
Etravirine
Autor(es)
Afiliação
Université Pierre et Marie Curie. Paris, France./ Hôspital Pitié-Salpêtrière. Service de las Maladies Infectieuses et Tropicales. Paris, France.
Hospital Universitari Germans Trias i Pujol. Barcelona, España./ IrsiCaixa Fundación. Barcelona, España.
Private Practice. Los Angeles, CA, USA.
Clinique Médicale I'Actuel. Montreal, QC, Canada.
Hôspital Saint-Louis. Service de las Maladies Infectieuses et Tropicales. Paris, France./ University of Paris Diderot. Paris, France.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Kaiser Permanente. Los Angeles, California, USA.
University of California San Diego. Division of Infectious Diseases. San Diego, CA, USA.
Tibotec BVBA. Beerse, Belgium.
Tibotec BVBA. Beerse, Belgium.
Tibotec BVBA. Beerse, Belgium.
Tibotec Inc. Titusville, NJ, USA.
Hospital Universitari Germans Trias i Pujol. Barcelona, España./ IrsiCaixa Fundación. Barcelona, España.
Private Practice. Los Angeles, CA, USA.
Clinique Médicale I'Actuel. Montreal, QC, Canada.
Hôspital Saint-Louis. Service de las Maladies Infectieuses et Tropicales. Paris, France./ University of Paris Diderot. Paris, France.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Kaiser Permanente. Los Angeles, California, USA.
University of California San Diego. Division of Infectious Diseases. San Diego, CA, USA.
Tibotec BVBA. Beerse, Belgium.
Tibotec BVBA. Beerse, Belgium.
Tibotec BVBA. Beerse, Belgium.
Tibotec Inc. Titusville, NJ, USA.
Resumo em Inglês
Durable efficacy and long-term safety of antiretroviral therapy are important goals in the management of treatment-experienced patients. The 96-week efficacy and safety of the non-nucleoside reverse transcriptase inhibitor (NNRTI) etravirine were evaluated in the Phase III DUET trials.
Palavras-chave em inglês
HIV-1Double-Blind Method
Darunavir
Reverse Transcriptase Inhibitors
Ritonavir
Treatment Outcome
Etravirine
Compartilhar